Evidence map›Paper›PMID 32039394›Full record

ArticleJHEP reports : innovation in hepatology2019

Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results.

Annieke C G van Baar, Ulrich Beuers, Kari Wong, Rehan Haidry, Guido Costamagna, Alia Hafedi, Jacques Deviere, Soumitra S Ghosh, Juan Carlos Lopez-Talavera, Leonardo Rodriguez and 3 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHEP reports : innovation in hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Endoscopic sleeve gastroplasty - minimally invasive treatment for non-alcoholic fatty liver disease and obesity.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2021
    Article
  15. Review
  16. Article
  17. Bariatric and Metabolic Endoscopy: A New Paradigm.Clinical and translational gastroenterology · 2021
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 6 countries.

Annieke C G van BaarDepartment of Gastroenterology & Hepatology, Amsterdam University Medical Centers, location Academic Medical Center, Amsterdam, The Netherlands.
Ulrich BeuersDepartment of Gastroenterology & Hepatology, Amsterdam University Medical Centers, location Academic Medical Center, Amsterdam, The Netherlands.
Kari WongMetabolon, Inc., Morrisville, NC, United States.
Rehan HaidryDepartment of Gastroenterology, University College Hospital NHS Foundation Trust, London, United Kingdom.
Guido CostamagnaDigestive Endoscopy Unit. Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.
Alia HafediDepartment of Gastroenterology, Erasme University Hospital, Brussels, Belgium.
Jacques DeviereDepartment of Gastroenterology, Erasme University Hospital, Brussels, Belgium.
Soumitra S GhoshDoon Associates LLC, San Diego, CA, United States.
Juan Carlos Lopez-TalaveraFractyl Laboratories, Inc., Lexington, MA, United States.
Leonardo RodriguezCCO Clinical Center for Diabetes, Obesity and Reflux, Santiago, Chile.
Manoel P Galvao NetoEndovitta Institute, Sao Paulo, Brazil.
Arun SanyalDepartment of Gastroenterology & Hepatology, Virginia Commonwealth University, Richmond, VA, United States.
Jacques J G H M BergmanDepartment of Gastroenterology & Hepatology, Amsterdam University Medical Centers, location Academic Medical Center, Amsterdam, The Netherlands.
Academic Medical Center · NLErasmus Hospital · BEAgostino Gemelli University Polyclinic · ITEngineering Associates (United States) · USFaculdade de Medicina do ABC · BRFractyl (United States) · USMetabolon (United States) · USUniversity College London · GBVirginia Commonwealth University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insulin resistance is a core pathophysiological defect underscoring type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD). Both conditions improve with duodenal exclusion surgery. Duodenal mucosal resurfacing (DMR) is an endoscopic intervention developed to treat metabolic disease which has been shown to improve glycaemia in patients with poorly controlled T2DM. Herein, we aimed to further analyse the effects of DMR on hepatic and metabolic parameters in this patient cohort.

methodsEighty-five patients with T2DM who received endoscopic DMR treatment were enrolled from 5 centres and followed up for 6 months. We assessed safety in all patients. Efficacy was evaluated in patients who received at least 9 cm of duodenal ablation (n = 67). Endpoints included HbA1c, fasting plasma glucose, weight and aminotransferase levels. Metabolomic analysis was conducted in a subgroup (n = 14). Data were analysed using paired

resultsThe DMR procedure was completed with no intraprocedural complications in the entire cohort. HbA1c was lower 6 months after DMR than at baseline (7.9 ± 0.2%

conclusionHydrothermal ablation of the duodenum by DMR elicits a beneficial metabolic response in patients with T2DM. DMR also improves hepatic indices, potentially through an insulin-sensitizing mechanism. These encouraging data deserve further evaluation in randomized controlled trials. LAY SUMMARY: Hydrothermal duodenal mucosal resurfacing (DMR) is an endoscopic technique designed to treat metabolic disease through ablation of the duodenal mucosa. DMR is a safe procedure which improves glycaemia and hepatic indices in patients with type 2 diabetes mellitus. DMR is an insulin-sensitizing intervention which can be complementary to lifestyle intervention approaches and pharmacological treatments aimed at preserving the pancreas and liver from failure. DMR is a potential therapeutic solution for patients with type 2 diabetes and fatty liver disease.

Indexed as

Aminotransferase levelsBlood GlucoseDuodenal Mucosal ResurfacingGlycated Haemoglobin A1cInsulin ResistanceMetabolic SyndromeMetabolomicsNAFLDNon-Alcoholic Fatty Liver DiseaseT2DMtherapeutic endoscopyType 2 Diabetes Mellitus

Identifiers

PMID32039394
PMCPMC7005649
OpenAlexW2984051241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.